US2013150448A1PendingUtilityA1

Dimeric double metal salts of (-) hydroxycitric acid, methods of making and uses of same

Assignee: GLYKON TECHNOLOGIES GROUP LLCPriority: Dec 15, 2006Filed: Feb 4, 2013Published: Jun 13, 2013
Est. expiryDec 15, 2026(~0.4 yrs left)· nominal 20-yr term from priority
A61P 3/06A61P 3/00A61P 3/04C07C 59/245A61K 31/19
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to soluble dimeric double metal salt compositions of (−)-hydroxycitric acid (“HCA”), as well as methods for making and using the same. The invention provides dimeric double metal salts of group IA and IIA of HCA (hereinafter, “DDM-HCAs”). The present invention provides methods to make DDM-HCAs of the invention which can be employed to alter the polar/ionic qualities of HCA salts and derivatives to improve solubility of HCA compositions. DDM-HCAs of the invention are soluble HCA-containing compositions useful as dietary supplements and suitable for manipulations under those conditions necessary for tabletting, encapsulation, and the production of dry powders, particularly for use as a beverage premix. Methods of use of the composition include treatment for suppression of appetite, for weight loss, for an increase in the rate of fat metabolism, for reduction in blood lipids and postprandial lipemia, and to increase the plasma level of (−)-hydroxycitric acid.

Claims

exact text as granted — not AI-modified
1 . A composition comprising at least one dimeric, double metal salt of group IA and group HA of (−)-hydroxycitric acid selected from the group consisting of: Formula I; Formula II; and Formula III, or any mixture thereof, as given below: 
       
         
           
                 
                 
                 
               
                     
                 
                   Formula I 
                   Formula II 
                   Formula III 
                 
                     
                 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                   
                     
                       
                       
                           
                           
                       
                     
                   
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
             
                
                
                
               
               
                
                
               
            
           
         
         wherein X is IIA group metal: Be, Mg, Ca, Sr, Ba, or Ra; 
         wherein Y is IA group metal: Li, Na, K, Rb, Cs, or Fr; and 
         wherein the relative molar ratio of IIA group metal to IA group metal is from at least about 1.0:3.5 to at least about 1.0:4.5. 
       
     
     
         2 . The composition of  claim 1 , wherein (i) X is magnesium metal; (ii) Y is potassium metal; and (iii) the relative molar ratio of magnesium metal to potassium metal is from at least about 1.0:3.5 to at least about 1.0:4.5. 
     
     
         3 . The composition of  claim 1 , wherein the composition is formulated in a dry delivery system. 
     
     
         4 . The composition of  claim 3 , wherein the dry delivery system is selected from the group consisting of: a tablet; a dry powder; and a dry meal replacement mixture. 
     
     
         5 . The composition of  claim 1 , wherein the composition is formulated in a liquid delivery system. 
     
     
         6 . The composition of  claim 5 , wherein the liquid delivery system is selected from the group consisting of: a capsule; a caplet; and a beverage. 
     
     
         7 . The composition of  claim 1 , wherein the composition is formulated for oral delivery in a form selected from the group consisting of: a tablet; a caplet; and a capsule. 
     
     
         8 . The composition of  claim 1 , further comprising a pharmaceutically-acceptable carrier. 
     
     
         9 . The composition of  claim 1 , wherein the total chloride content is less than about 1% by weight. 
     
     
         10 . The composition of  claim 1 , wherein the total chloride content is less than about 0.6% by weight. 
     
     
         11 - 25 . (canceled)

Join the waitlist — get patent alerts

Track US2013150448A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.